Relmada Therapeutics, Inc. (RLMD)

NASDAQ: RLMD · IEX Real-Time Price · USD

2.94

-0.21 (-6.67%)

At close: Sep 28, 2023, 4:00 PM

2.75

-0.19 (-6.46%)

Pre-market: Sep 29, 2023, 7:09 AM EDT

Income Statement (Annual)

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018	2017	2016	2015
Selling, General & Admin	47.93	35.08	24.87	7.25	3.97	5.93	10.01	9.23
Research & Development	113.32	90.62	35.97	7.86	2.94	1.29	6.21	7.87
Operating Expenses	161.25	125.7	60.84	15.11	6.92	7.22	16.22	17.1
Operating Income	-161.25	-125.7	-60.84	-15.11	-6.92	-7.22	-16.22	-17.1
Interest Expense / Income	0	0	0	0.1	1.34	0	0	0
Other Expense / Income	-4.21	0.05	-1.38	-0.21	0.71	-0.93	-13.24	3.7
Pretax Income	-157.04	-125.75	-59.46	-15.01	-8.96	-6.29	-2.97	-20.8
Net Income	-157.04	-125.75	-59.46	-15.01	-8.96	-6.29	-2.97	-20.8
Shares Outstanding (Basic)	30	18	16	9	3	3	3	2
Shares Outstanding (Diluted)	30	18	16	9	3	3	3	2
Shares Change	68.80%	12.56%	68.75%	194.65%	3.90%	4.10%	16.68%	-
EPS (Basic)	-5.30	-7.16	-3.81	-1.62	-2.86	-2.08	-1.04	-8.36
EPS (Diluted)	-5.30	-7.16	-3.81	-1.62	-2.86	-2.08	-1.04	-8.36
Free Cash Flow	-103.8	-91.87	-27.81	-12.09	-6.01	-6.52	-13.71	-16.25
Free Cash Flow Per Share	-3.50	-5.23	-1.78	-1.31	-1.92	-2.16	-4.73	-6.54
EBITDA	-157.04	-125.75	-59.45	-14.9	-7.62	-6.2	-2.92	-20.79
Depreciation & Amortization	0	0	0	0	0	0.09	0.05	0.01
EBIT	-157.04	-125.75	-59.46	-14.9	-7.62	-6.29	-2.97	-20.8

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).